Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX:PBT)
Filing Type: Form 6-K (Interim Financial Report)
Reporting Period: Half-year ended 31 December 2013
Business Overview: Prana is a development-stage medical biotechnology company focused on researching treatments for Alzheimer's Disease, Huntington's Disease, and other neurodegenerative disorders. The company's lead compound is PBT2, a Metal Protein Attenuating Compound (MPAC).
Key Financial Metrics
| Metric | Half-Year 2013 | Half-Year 2012 |
|---|---|---|
| Revenue (Interest income) | A$189,588 | A$39,577 |
| Other Income (R&D Tax Concession & Grants) | A$1,460,480 | A$2,265,883 |
| Net Loss (After Tax) | (A$7,928,392) | (A$4,332,321) |
| Loss Per Share (Basic & Diluted) | (1.97) cents | (1.36) cents |
| Research & Development Expenses | A$6,849,527 | A$3,982,589 |
| Cash and Cash Equivalents (End of Period) | A$19,300,061 | A$8,842,077 |
| Net Tangible Assets per Share | 4.75 cents | 3.66 cents (as at 30 June 2013) |
| Net Operating Cash Flow | (A$7,435,475) | (A$4,548,480) |
| Net Financing Cash Flow | A$13,085,321 | A$7,839,983 |
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased 379% to A$189,588, driven entirely by higher interest income due to increased cash balances.
- Loss Expansion: Net loss increased 83% to A$7.93 million. This was primarily due to a significant rise in Research and Development (R&D) expenses, which grew from A$3.98 million to A$6.85 million.
- Other Income Decline: Other income decreased by approximately 35% to A$1.46 million, largely due to a reduction in the R&D Tax Concession recognized (A$1.46m vs A$2.19m in the prior period).
- Cash Position: Cash reserves increased by A$5.64 million to A$19.3 million, supported by net financing inflows of A$13.1 million from share issuances and option exercises.
- Foreign Exchange: The company recorded a foreign exchange gain of A$235,697, compared to a loss of A$75,661 in the prior period.
Outlook, Management Commentary, and Risks
Clinical Trial Progress
- Reach2HD (Huntington's Disease): Dosing completed in July 2013 with 95% participant retention. Results were released on 18 February 2014. The Data Safety Monitoring Board (DSMB) allowed the trial to continue without protocol changes.
- IMAGINE (Alzheimer's Disease): Dosing completed in December 2013 with 95% retention. Results are expected in Q1 2014. An open-label extension study (IMAGINE-Ext) commenced with 83% of patients enrolling.
- PBT434 (Parkinson's): Received a £150,000 grant from Parkinson's UK for further mechanism of action research.
Capital Raising and Liquidity
- ATM Facility: The company utilized its At-The-Market (ATM) facility, issuing 5.9 million ADSs for gross proceeds of A$17.59 million (US$16.99 million) during the period.
- Option Exercises: Significant option exercises occurred both during the period and subsequent to the reporting date, raising additional capital (A$3 million during the period; A$1.39 million post-period).
- Going Concern: Directors believe cash on hand plus subsequent inflows (including a A$4.09 million R&D tax refund received post-period) are sufficient to fund operations for at least 12 months.
Risks and Contingencies
- Development Stage: As a pre-revenue biotech, the company relies on capital markets and grants to fund operations until products are marketable.
- Financial Liabilities: The company holds a Convertible Promissory Note and warrants issued to the Alzheimer's Drug Discovery Foundation (ADDF), classified as financial liabilities subject to fair value revaluation.
- Regulatory: Success depends on the outcomes of ongoing clinical trials and regulatory approvals.
Investor Verification Checklist
- Clinical Results: Verify the specific data released on 18 February 2014 regarding the Reach2HD trial and the anticipated Q1 2014 release for the IMAGINE trial.
- Cash Burn Rate: Confirm the sustainability of the A$19.3 million cash balance against the current R&D burn rate of approximately A$6.85 million per half-year.
- Dilution Impact: Assess the impact of the 20 million+ unlisted options on issue and the ongoing ATM facility on future share price and ownership dilution.
- R&D Tax Refund: Confirm the receipt and timing of the A$4.09 million R&D tax refund mentioned as a subsequent event.
- Convertible Note Terms: Review the conversion triggers for the ADDF Convertible Promissory Note, specifically regarding future equity financings.